Pim Heckman speaks to us about the impact that receiving one of the three 2021 CANTAB Research Grant prizes will have on his research into clearing COVID-19 cognitive brain fog
Jamileth More recently spoke to us about the impact that receiving one of the three 2021 CANTAB Research Grant prizes will have on her research into monitoring protocol of COVID-19 patients survivors of mechanical ventilation.
CANTAB used to assist with identifying patients with mild cognitive impairment and subjective cognit
Dr. Andrea McGrattan, a Research Dietitian and Lecturer in Nutrition and Dietetics, spoke to us about her PhD research at Queen’s University Belfast, using CANTAB cognitive testing within a Mediterranean Diet feasibility study, “THINK-MED”, among people with cognitive impairment.
Alexander Friend shares the role CANTAB played in the research he conducted on cognitive impairment at high-altitude while at The University of Birmingham.
Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines guidance for including older adults in clinical trials.
Read on for session two: key design considerations when including elderly patients in clinical trials, with a focus on cognitive assessment.
Professor Eirini Flouri spoke to us about why they chose CANTAB to investigate children’s spatial working memory in a large, epidemiological study.
We caught up with Dr Arvin Haghighatfard to discuss why he chose CANTAB to investigate the effects of neuregulin 1 on executive dysfunction in autism spectrum disorder.
Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.
Mood disorders affect 5-10% of the adult population in a given year. The most common mood disorders are major depressive disorder, dysthymia, and bipolar disorder. Here we explore the six CANTAB tests for objectively measuring cognitive function in depression.